Suppression of carboxylesterases by imatinib mediated by the down‐regulation of pregnane X receptor
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Pharmacology"
DOI: 10.1111/bph.13731
Abstract: Imatinib mesylate (IM) is a first‐line treatment for chronic myeloid leukaemia (CML) as a specific inhibitor of BCR‐ABL tyrosine kinase. As IM is widely used in CML, in combination with other drugs, the effects of… read more here.
Keywords: regulation pregnane; mediated regulation; carboxylesterases imatinib; imatinib mediated ... See more keywords